BiomeBank
Adelaide, Australia· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $10M
Overview
Australian biotech leveraging co‑cultured gut microbiome consortia to deliver regulated, scalable therapies for C. and and ulcerative colitis.
GastroenterologyImmunologyMetabolismNeurologyOncologyInfectious Disease
Technology Platform
CONSORTIOME® is a proprietary co‑culturing platform that assembles complex, defined microbial consortia replicating >90% of the gene families of a healthy human gut, enabling scalable, reproducible microbiome therapeutics.
Opportunities
Scaling the CONSORTIOME® platform for global indications and securing regulatory approvals for oral FMT capsules could unlock multi‑billion‑dollar market potential.
Risk Factors
Regulatory uncertainty, manufacturing scale‑up challenges, and competition from established microbiome players could impede commercial rollout.
Competitive Landscape
Key competitors include Seres Therapeutics, Finch Therapeutics, and Rebiotix; BiomeBank differentiates itself through co‑cultured consortia that offer greater functional diversity and manufacturing consistency than single‑strain or donor‑derived products.